NZ518167A - Composition comprising an alpha-amylase inhibitor, inulin, fructooligosaccharides and a fat inhibitor for treating obesity and preventing weight gain or causing weight loss - Google Patents
Composition comprising an alpha-amylase inhibitor, inulin, fructooligosaccharides and a fat inhibitor for treating obesity and preventing weight gain or causing weight lossInfo
- Publication number
- NZ518167A NZ518167A NZ518167A NZ51816700A NZ518167A NZ 518167 A NZ518167 A NZ 518167A NZ 518167 A NZ518167 A NZ 518167A NZ 51816700 A NZ51816700 A NZ 51816700A NZ 518167 A NZ518167 A NZ 518167A
- Authority
- NZ
- New Zealand
- Prior art keywords
- inhibitor
- alpha
- composition
- treating obesity
- fructooligosaccharides
- Prior art date
Links
- 101710171801 Alpha-amylase inhibitor Proteins 0.000 title abstract 3
- 239000003392 amylase inhibitor Substances 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 230000004584 weight gain Effects 0.000 title abstract 2
- 235000019786 weight gain Nutrition 0.000 title abstract 2
- 230000004580 weight loss Effects 0.000 title abstract 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 title 1
- 229920001202 Inulin Polymers 0.000 title 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 title 1
- 229940029339 inulin Drugs 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 244000046052 Phaseolus vulgaris Species 0.000 abstract 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 abstract 1
- 108010064851 Plant Proteins Proteins 0.000 abstract 1
- 235000014633 carbohydrates Nutrition 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 235000021118 plant-derived protein Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9921229.2A GB9921229D0 (en) | 1999-09-08 | 1999-09-08 | Compositions |
| PCT/GB2000/003472 WO2001017369A1 (en) | 1999-09-08 | 2000-09-08 | Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of 'fast sugars' |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ518167A true NZ518167A (en) | 2003-03-28 |
Family
ID=10860574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ518167A NZ518167A (en) | 1999-09-08 | 2000-09-08 | Composition comprising an alpha-amylase inhibitor, inulin, fructooligosaccharides and a fat inhibitor for treating obesity and preventing weight gain or causing weight loss |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1213972B1 (https=) |
| JP (1) | JP2003508467A (https=) |
| KR (1) | KR100594520B1 (https=) |
| AT (1) | ATE238689T1 (https=) |
| AU (1) | AU777044B2 (https=) |
| CA (1) | CA2383720A1 (https=) |
| DE (1) | DE60002484T2 (https=) |
| DK (1) | DK1213972T3 (https=) |
| ES (1) | ES2199174T3 (https=) |
| GB (2) | GB9921229D0 (https=) |
| NO (1) | NO314922B1 (https=) |
| NZ (1) | NZ518167A (https=) |
| PT (1) | PT1213972E (https=) |
| WO (1) | WO2001017369A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2426552C2 (ru) * | 2005-12-22 | 2011-08-20 | Индена С.П.А. | Экстракты phaseolus vulgaris, их применение и композиции, содержащие их |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217556B1 (en) | 2000-12-23 | 2007-05-15 | Pfizer Inc | Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease |
| US7601528B1 (en) | 2000-12-23 | 2009-10-13 | Elan Pharmaceuticals, Inc. | Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease |
| US7384773B1 (en) | 2001-05-10 | 2008-06-10 | Pfizer Inc | Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof |
| US6797287B2 (en) | 2001-09-25 | 2004-09-28 | Pharmachem Laboratories, Inc. | Phaseolamin compositions and methods for using the same |
| US7108869B2 (en) | 2002-11-07 | 2006-09-19 | Access Business Group International Llc | Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors |
| ITMI20030391A1 (it) * | 2003-03-04 | 2004-09-05 | S I I T S R L Servizio Internaz Ionale Imballa | Formulazioni anticarie a base di faseolamina. |
| JP5285852B2 (ja) * | 2006-12-28 | 2013-09-11 | 株式会社ファンケル | Ｄｆａｉｉｉの製造方法及びｄｆａｉｉｉ高含有植物エキス |
| US20100330137A1 (en) * | 2008-03-10 | 2010-12-30 | Mauro Mantovani | High bioavailability formulation of mangosteen and manufacturing process thereof |
| CA2751227C (en) * | 2009-02-02 | 2021-10-26 | Laila Nutraceuticals | Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome |
| JP2011079752A (ja) * | 2009-10-05 | 2011-04-21 | Kracie Home Products Ltd | 膵リパーゼ阻害剤並びにそれを含有する飲食品組成物及び医薬品組成物 |
| CN103478738B (zh) * | 2013-09-17 | 2016-02-10 | 深圳太太药业有限公司 | 一种具有减肥塑身及体重管理作用的组合物 |
| CN106686988A (zh) * | 2014-09-19 | 2017-05-17 | 雀巢产品技术援助有限公司 | 用于降低伴侣动物碳水化合物吸收的方法和配制物 |
| CN106036342A (zh) * | 2016-06-14 | 2016-10-26 | 安徽平唐微食疗科技有限公司 | 适合于糖尿病人群食用的膳食补充固体饮料及其制备方法 |
| IT201700078389A1 (it) * | 2017-07-13 | 2019-01-13 | Mv Medical Solutions | Composizione utile nella prevenzione o trattamento degli stati di malassorbimento secondari a chirurgia bariatrica in soggetti obesi. |
| AU2020281621B2 (en) * | 2019-05-24 | 2025-09-11 | Cosucra Groupe Warcoing S.A. | Composition comprising inulin and protein |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4010258A (en) * | 1974-03-15 | 1977-03-01 | Ajinomoto Co., Inc. | Microbial amylase inhibitor and preparation thereof with the use of streptomyces diasticus var. amylostaticus |
| JP2757405B2 (ja) * | 1988-12-09 | 1998-05-25 | 日清製粉株式会社 | 小麦から得られるα−アミラーゼインヒビターを含有するダイエット剤 |
| US5612039A (en) * | 1994-03-14 | 1997-03-18 | Nini E. Policappelli | Dietary supplement |
| WO2000043036A2 (en) * | 1999-01-22 | 2000-07-27 | Hunza Di Maria Carmela Marazzita S.A.S. | Lipoprotein complexes and compositions containing them |
-
1999
- 1999-09-08 GB GBGB9921229.2A patent/GB9921229D0/en not_active Ceased
-
2000
- 2000-09-08 ES ES00958855T patent/ES2199174T3/es not_active Expired - Lifetime
- 2000-09-08 AU AU70269/00A patent/AU777044B2/en not_active Ceased
- 2000-09-08 KR KR1020027003087A patent/KR100594520B1/ko not_active Expired - Fee Related
- 2000-09-08 AT AT00958855T patent/ATE238689T1/de not_active IP Right Cessation
- 2000-09-08 PT PT00958855T patent/PT1213972E/pt unknown
- 2000-09-08 WO PCT/GB2000/003472 patent/WO2001017369A1/en not_active Ceased
- 2000-09-08 NZ NZ518167A patent/NZ518167A/xx not_active IP Right Cessation
- 2000-09-08 DE DE60002484T patent/DE60002484T2/de not_active Expired - Fee Related
- 2000-09-08 DK DK00958855T patent/DK1213972T3/da active
- 2000-09-08 JP JP2001521170A patent/JP2003508467A/ja not_active Withdrawn
- 2000-09-08 EP EP00958855A patent/EP1213972B1/en not_active Expired - Lifetime
- 2000-09-08 CA CA002383720A patent/CA2383720A1/en not_active Abandoned
- 2000-09-08 GB GB0127158A patent/GB2364498A/en not_active Withdrawn
-
2002
- 2002-03-08 NO NO20021160A patent/NO314922B1/no not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2426552C2 (ru) * | 2005-12-22 | 2011-08-20 | Индена С.П.А. | Экстракты phaseolus vulgaris, их применение и композиции, содержащие их |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2383720A1 (en) | 2001-03-15 |
| DK1213972T3 (da) | 2003-08-18 |
| GB9921229D0 (en) | 1999-11-10 |
| EP1213972B1 (en) | 2003-05-02 |
| DE60002484D1 (de) | 2003-06-05 |
| PT1213972E (pt) | 2003-09-30 |
| ATE238689T1 (de) | 2003-05-15 |
| AU777044B2 (en) | 2004-09-30 |
| AU7026900A (en) | 2001-04-10 |
| EP1213972A1 (en) | 2002-06-19 |
| KR20020045605A (ko) | 2002-06-19 |
| ES2199174T3 (es) | 2004-02-16 |
| NO314922B1 (no) | 2003-06-16 |
| GB2364498A (en) | 2002-01-30 |
| KR100594520B1 (ko) | 2006-07-19 |
| NO20021160L (no) | 2002-03-27 |
| NO20021160D0 (no) | 2002-03-08 |
| DE60002484T2 (de) | 2004-03-18 |
| GB0127158D0 (en) | 2002-01-02 |
| JP2003508467A (ja) | 2003-03-04 |
| WO2001017369A1 (en) | 2001-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ518167A (en) | Composition comprising an alpha-amylase inhibitor, inulin, fructooligosaccharides and a fat inhibitor for treating obesity and preventing weight gain or causing weight loss | |
| BG104680A (en) | Celecoxib compositions | |
| MY133569A (en) | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors | |
| ID28295A (id) | Komposisi-komposisi permen | |
| MXPA04002751A (es) | Modificacion del comportamiento de alimentacion. | |
| AU4304196A (en) | Novel sulfonamides | |
| AU2672995A (en) | {a}-annelated pyrrole derivatives and pharmaceutical uses thereof | |
| LTIP555A (en) | Orally adminsterable drugs for the treatmentof central dopamine deficiency conditions | |
| EP1637137A3 (en) | Method and composition for administering a cyclooxygenase-2 inhibitor to animals | |
| WO2001081332A3 (en) | 2-fluorobenzenesulfonyl compounds for the treatment of inflammation | |
| BG104135A (en) | Diabetes treatment with thiazolydindion, a form increasing the insulin and biguanide secretion | |
| MX9701816A (es) | Cepas de bacterias y composicion farmaceutica que contiene dichas cepas y uso de la misma para prevenir y tratar enfermedades asociadas con el metabolismo alterado de acidos biliares o causadas por el mismo. | |
| IL126235A (en) | Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use | |
| MY135840A (en) | Crystals of an oxyiminoalkanoic acid derivative and their use as antidiabetics | |
| WO2001035902A3 (en) | Stabilized thyroxine compounds | |
| BR0015102A (pt) | Bactérias de ácido latico para o tratamento e/ou profilaxia de giardìase | |
| AU4738500A (en) | Improved method for treating mammals with modified mammalian blood | |
| MD670G2 (ro) | Remediu cu acţiune imunomodulatoare | |
| AU2566101A (en) | Compounds and methods for the treatment of pain | |
| MY123805A (en) | Stabilized pharmaceutical composition based on quinupristine and dalfopristine and their preparation. | |
| George | Other infections of skin, soft tissue, and muscle. | |
| HK1051033A1 (zh) | 白细胞介素5基因表达抑制剂 | |
| DE69717277D1 (en) | Imidazopyridine | |
| WO1999020259A3 (en) | Compositions containing thiamphenicol and diclofenac | |
| WO2002038144A8 (en) | The use of tiagabine for treatment of diabetic neuropathy and migraine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| LAPS | Patent lapsed |